IP Library › Granted Patent US 12,662,685
Granted Patent B2
US 12,662,685 · App. 17/271,814 · Granted Jun 23, 2026

Self-inactivating transposase plasmids and uses thereof

Inventors: Michael C. Jensen (Seattle, WA); Joshua Gustafson (Seattle, WA); Joseph Cheng (Seattle, WA); Rachel Wilson (Seattle, WA); Kamila Sabina Gwiazda (Seattle, WA); Jeremy Bjelajac (Seattle, WA)
Assignee: Seattle Children's Hospital
C12N15/85C12N2800/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,662,685
App. No.
17/271,814
Filed
Feb 26, 2021
Granted
Jun 23, 2026
Kind
B2
Art Unit
1632
USPC
435/320.1
Abstract

Some embodiments provided herein relate to gene delivery systems and methods using a single plasmid that carries a self-inactivating transposase gene and a corresponding transposon. Some embodiments include nucleic acids having certain sequences, vector including such nucleic acids, and compositions including the vectors.

Claims (18)

1 . A vector for delivery of a payload into a cell genome, the vector comprising (a), (b), and (c) in a 5′ to 3′ order:

(a) a first nucleic acid comprising (i) a nucleotide sequence encoding a transposase, and (ii) an intron comprising a first transposase recognition site (TRS), wherein the intron is inserted into the nucleotide sequence encoding the transposase;

(b) a second nucleic acid encoding the payload; and

(c) a second TRS.

2 . The vector of claim 1 , wherein the vector is a circular vector.

3 . The vector of claim 1 , wherein the transposase is a Tn5 transposase, a MuA transposase, a Tn552 transposase, or a mariner transposase.

4 . The vector of claim 1 , wherein the transposase is encoded by a sequence having at least 90% sequence identity to the nucleotide sequence of SEQ ID NO:01 or SEQ ID NO:03.

5 . The vector of claim 1 , wherein the intron is derived from a nucleic acid lacking the first TRS and, wherein the nucleic acid lacking the first TRS comprises a sequence having at least 90% sequence identity to the nucleotide sequence of SEQ ID NO:02.

6 . The vector of claim 1 , wherein the first TRS and the second TRS are both derived from a transposon selected from a Tn5 transposon, a MuA transposon, a Tn552 transposon, or a mariner transposon.

7 . The vector of claim 1 , wherein the first TRS and the second TRS comprise a sequence having at least 90% sequence identity to the nucleotide sequence of SEQ ID NO:05 or SEQ ID NO:13.

8 . The vector of claim 1 , wherein the payload encodes a therapeutic protein.

9 . The vector of claim 1 , further comprising a first promoter operably linked to the first nucleic acid.

10 . The vector of claim 1 , further comprising a selectable marker.

11 . The vector of claim 10 , wherein the selectable marker encodes a dihydrofolate reductase (DHFR).

12 . The vector of claim 1 , further comprising a nucleic acid encoding a first polyA signal operably linked to the second nucleic acid, or a second polyA signal operably linked to the third nucleic acid.

13 . A cell comprising the vector of claim 1 .

14 . The cell of claim 13 , wherein the cell is a mammalian cell.

15 . The cell of claim 14 , wherein the cell is a human cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2026
From: JENSEN, MICHAEL C.; GUSTAFSON, JOSHUA; CHENG, JOSEPH; WILSON, RACHEL; GWIAZDA, KAMILA SABINA; BJELAJAC, JEREMY
To: SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)
Reel/Frame 073702/0067 →
Continuity (2)
Provisional Application 62724236 · Aug 28, 2019
Related Publication 20210324407A1 · Oct 21, 2021
References Cited (31)
US 20100240133A1 · Brivanlou · 2010 [cited by examiner]
US 20100287633A1 · Ostertag et al. · 2010 [cited by applicant]
US 20170159070A1 · Wu · 2017 [cited by applicant]
WO WO9523875 · 1995 [cited by applicant]
WO WO2015157579A2 · 2015 [cited by examiner]
WO WO2017054647A1 · 2017 [cited by applicant]
Zhang et al. Distributions of Transposable Elements Reveal Hazardous Zones in Mammalian Introns. PLoS Comput Biol. May 2011;7(5):e1002046 (Year: 2011). [cited by examiner]
Boualle {grave over ( )}gue et al. Molecular Evolution of piggyBac Superfamily: From Selfishness to Domestication. Genome Biol Evol. Feb. 1, 2017;9(2):323-339. (Year: 2017). [cited by examiner]
Wakabayashi-It et al. Characterization of the Regulatory Elements in the Promoteorf the Human Elongation Factor-la Gene. J Biol Chem. Nov. 25, 1994;269(47):29831-7. (Year: 1994). [cited by examiner]
Cracking the Code of life. Nova Online (accessed at: https://www.pbs.org/wgbh/nova/genome/expl_05_introns.html) (Year: 2001). [cited by examiner]
Derived. Dictionary.Com (accessed at: https://www.dictionary.com/browse/derived) (Year: 2024). [cited by examiner]
Chakraborty, Syandan et al., “Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis” Scientific Reports, Dec. 2014, pp. 1-9, vol. 4, No. 7403. [cited by applicant]
International Search Report for PCT/US2019/048663 dated Jan. 6, 2020. [cited by applicant]
Brown et al., Apr. 1989, Retroviral integration: struciure of the initial covalent product and its precursor, and a role for the viral IN protein, Proc. Natl. Acad. Sci. USA, 86:2525-2529 [cited by applicant]
Colegio et al., Apr. 2001, In vitro transposition system for efficient generation of random mutants of campylobacter jejuni, J. Bacteriol., 183(7):2384-2388. [cited by applicant]
Devine et al., 1994, Efficient integration of artificial transposons into plasmid targets in vitro: a useful tool for DNA mapping, sequencing and genetic analysis, Nucleic Acids Res., 22(18):3765-3772. [cited by applicant]
Ichikawa et al., Nov. 5, 1990, In vitro transposition of transposon Tn3*, J. Biol. Chem., 265(31):18829-18832. [cited by applicant]
Kirby et al., 2002, Cryptic plasmids of [cited by applicant]
Lampe et al., 1995, The phage Mu transpososome core: DNA requirements for assembly and function, EMBO J., 15:5470-5479. [cited by applicant]
Lemaigre et al., “Transcriptional control of genes that regulate glycolysis and gluconeogenesis in adult liver,” Biochem. J. (1994) 303:1-14. [cited by applicant]
Loeken, 1993, Effects of mutation of the CREB binding site of the somatostatin promoter on cyclic AMP responsiveness in CV-1 cells, Gene Expr. 3(3):253-264. [cited by applicant]
McGehee et al., Apr. 1993, Differentiation-specific element: a cis-acting developmental switch required for the sustained transcriptional expression of the angiotensinogen gene during hormonal-induced differentiation of… [cited by applicant]
Ohtsubo et al., 1996, Bacterial insertion sequences, Curr. Top. Microbiol. Immunol. 204:1-26. [cited by applicant]
O'Reilly et al., Oct. 5, 1992, Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-beta 2 promoter, J. Biol. Chem. 267:19938-19943. [cited by applicant]
Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, Cold Springs Harbor, NY (T)C). [cited by applicant]
Singleton et al., 1994, Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons, New York, NY (cover page). [cited by applicant]
Treisman, Feb. 1, 1990, The SRE: a growth factor responsive transcriptional regulator. (PMID:2133110), Seminars in Cancer Biology, 1(1):47-58. [cited by applicant]
Watson et al., eds., 1987, Molecular Biology of the Gene, 4th ed., The Benjamin/Cummings Publishing Company, Inc. (TOC). [cited by applicant]
Wilson et al., Dec. 2007, New transposon delivery plasmids for insertional mutagenesis in bacillus anthracis, J. Microbiol. Methods 71(3):332-335. [cited by applicant]
Ye et al., Oct. 14, 1994, Characterization of a silencer regulatory element in the human interferon-gamma promoter, J. Biol. Chem., 269:25728-25734. [cited by applicant]
Zhang et al., Oct. 2009, A novel mechanism of transposon-mediated gene activation, PLoS Genet. 5(10):e1000689. [cited by applicant]